2seventy Bio Finishes $40M Deal With Novo Nordisk

An asset purchase agreement (APA) was struck by US-based 2seventy bio to sell their haemophilia A candidate to Novo Nordisk.

Under the terms of the arrangement, 2seventy bio may receive up to $40 million, ending a research collaboration that was started in 2019. The agreement was centred on creating a gene editing treatment for haemophilia A patients.

Due to a deficiency in blood-clotting proteins, haemophilia is an uncommon condition in which blood does not clot normally.

Additionally, Novo Nordisk will be given access to 2seventy’s MegaTAL in vivo gene editing technology, which may be used for purposes other than autoimmune illnesses and cancer research.

To keep working on the innovation, Novo Nordisk will welcome the seventy bio team members who were a part of the programme.

2seventy bio CEO Chip Baird stated: “Novo Nordisk has been a valued partner over the past five years, and we are confident that under their leadership, the promise of developing a new treatment approach for patients living with hemophilia A will continue to progress.”